Clinical Trials
18 trialsNCT07188532 2026-06-04
BEAR
Mayo Clinic
Phase NA Recruiting
NCT04172532 2026-06-02
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT07595224 2026-05-19
PostOP HYPOCxE
Siriraj Hospital
Phase NA Recruiting
NCT07566156 2026-05-11
EV-309
Astellas Pharma Inc
Phase 3 Recruiting
NCT07097142 2026-05-04
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NRG Oncology
Phase 3 Recruiting
NCT05917301 2026-04-17
PRONTO
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Recruiting
NCT07276360 2026-03-27
HypoRTCx-UG
Uganda Cancer Institute
Phase 2 Recruiting
NCT02701153 2026-03-10
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
Jonsson Comprehensive Cancer Center
Phase NA Recruiting
NCT07447570 2026-03-03
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT04278118 2026-02-17
HiPPI
Emory University
Phase NA Recruiting
NCT05109494 2026-01-28
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
University of Wisconsin, Madison
Phase 2 Recruiting
NCT06205316 2026-01-20
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
Phase 3 Recruiting
NCT06559540 2026-01-09
SWIFT RT
Washington University School of Medicine
Phase 2 Recruiting
NCT04683653 2025-12-29
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
University of Chicago
Phase 1/2 Recruiting
NCT06635980 2025-12-12
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
Mayo Clinic
Phase 2 Recruiting
NCT04430452 2025-12-08
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
University of California, San Francisco
Phase 2 Recruiting
NCT06379087 2025-07-10
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
Zhejiang Cancer Hospital
Phase 2 Recruiting
NCT06435260 2025-06-26
Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer
Hebei Medical University Fourth Hospital
Phase 2 Recruiting